Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received an average rating of “Moderate Buy” from the ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 10.88%, which has investors questioning if this is right time to buy.

Reports revenue RMB 980.7M vs. RMB 221.9M last year. Dajun Yang, CEO, said, “As we reflect on our achievements in 2024, I am delighted to ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...